MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update
Key Highlights
- ➤Q3 total revenue $101.9 million, up 24% year over year
- ➤Q3 commercial product revenue $45.0 million, up 102% year over year
- ➤Q3 net loss $23.2 million versus $8.0 million net income
- ➤Furoscix ReadyFlow shipments began mid-September after approval, reaching 75% of shipments
- ➤Nintedanib DPI Phase 1b results were positive; global Phase 2 trial underway
Expert Statements
Michael Castagna, Chief Executive Officer of MannKind
“The third quarter marked an important transition for MannKind as we shifted from delivering on three major catalysts to executing against them. We are focused on scaling two commercial launches while supporting three programs in IPF. Furoscix ReadyFlow is off to an exceptionally strong start, and we believe Furoscix will generate more revenue in the fourth quarter than it did in the first half of 2026. ReadyFlow significantly expands the opportunity ahead and reinforces our conviction that Furoscix can be transformational for MannKind and the patients we serve.”
* Q3 2026 total revenues of $101.9 million, +24% vs. Q3 2025 * Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025 * Furoscix ReadyFlow™ was approved and shipments commenced mid-September * Rapid adoption of Furoscix ReadyFlow, making up approximately 75% of the current weekly Furoscix shipments * Afrezza(®) pediatric launch accounts for an approximately 80% increase in average monthly new-to-brand prescriptions in Q3 vs. Q2 2026
* Pipeline Advancements * Reported positive Phase 1b INFLO-1 results, demonstrating tolerability of nintedanib DPI and clinical validation of Technosphere DPI technology in IPF; global Phase 2 trial underway
Get started
Create a free account to read the full story.